PG 760564Alternative Names: PG-760564
Latest Information Update: 26 Mar 2010
At a glance
- Originator Procter & Gamble
- Class Antirheumatics
- Mechanism of Action P38 mitogen-activated protein kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 30 Oct 2009 Warner Chilcott has acquired the global pharmaceutical business of Procter & Gamble